Bioinformatics analysis reveals potential candidate drugs for cervical cancer

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 5, 2013, Pages 1052-1058

  Ai, Zhihong ^a   Wang, Juan ^a   Xu, Yanli ^a   Teng, Yincheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bioinformatics analysis; Cervical cancer; Epidermal growth factor; Small molecule; Sub pathway

Indexed keywords

AG 028671; ANTINEOPLASTIC AGENT; BEPRIDIL; CICLOPIROX; DEFEROXAMINE; EPIDERMAL GROWTH FACTOR; ETACRYNIC ACID; ETOPOSIDE; METYRAPONE; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE; PROTEIN P53; PYRVINIUM EMBONATE; THIORIDAZINE; TRIFLURIDINE; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84880303119     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12022     Document Type: Article

References (47)

1. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic hpv types. J Manag Care Pharm 2010; 16: 217-230.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Einstein MH, Schiller JT, Viscidi RP et al. Clinician's guide to human papillomavirus immunology: Knowns and unknowns. Lancet Infect Dis 2009; 9: 347-356.
4. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA 2005; 102: 2490-2495.
5. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-1153.
6. KK F. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 1985; 55: 2123-2130.
7. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-26.
8. Yarden Y, Sliwkowski MX. Untangling the erbb signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
9. Hynes NE, Lane HA. Erbb receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
10. Kanehisa M. The kegg database. Novartis Found Symp 2002; 247: 91-101. Discussion 101-103, 119-128, 244-152.
11. Lamb J, Crawford ED, Peck D et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
12. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
13. Chen X, Xu J, Huang B et al. A sub-pathway-based approach for identifying drug response principal network. Bioinformatics 2011; 27: 649-654.
14. Li C, Li X, Miao Y et al. SubpathwayMiner: A software package for flexible identification of pathways. Nucleic Acids Res 2009; 37: e131.
15. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
16. Farooq A, Zhou MM. Structure and regulation of mapk phosphatases. Cell Signal 2004; 16: 769-779.
17. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 mapk signalling. Biochem J 2010; 429: 403-417.
18. Hommes DW, Peppelenbosch MP, van Deventer SJ. Mitogen activated protein (map) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003; 52: 144-151.
19. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
20. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
21. Stegh AH. Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Expert Opin Ther Targets 2012; 16: 67-83.
22. Goodsell DS. The molecular perspective: Epidermal growth factor. Oncologist 2003; 8: 496-497.
23. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of a431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983; 80: 1337-1341.
24. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-529.
25. Gill GN, Kawamoto T, Cochet C et al. Monoclonal antiepidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259: 7755-7760.
26. Kang S, Dong SM, Kim BR et al. Thioridazine induces apoptosis by targeting the pi3k/akt/mtor pathway in cervical and endometrial cancer cells. Apoptosis 2012; 17: 989-997.
27. Weir SJ, Patton L, Castle K, Rajewski L, Kasper J, Schimmer AD. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J Clin Pharm Ther 2011; 36: 128-134.
28. Kohler B, Anguissola S, Concannon CG, Rehm M, Kogel D, Prehn JH. Bid participates in genotoxic drug-induced apoptosis of hela cells and is essential for death receptor ligands' apoptotic and synergistic effects. PLoS ONE 2008; 3: e2844.
29. Huang TS, Lee CC, Chao Y et al. A novel podophyllotoxinderived compound gl331 is more potent than its congener vp-16 in killing refractory cancer cells. Pharm Res 1999; 16: 997-1002.
30. Hara K, Iwasaka T, Matsuo N et al. Effects of single and combined application of anti-cancer drugs on cervical adenocarcinoma. I. Antitumor activity in vitro. Acta Obstet Gynecol Scand 1995; 74: 330-335.
31. Maeda T, Ueda M, Yamada T et al. Sensitivity to etoposide in cultured cells from cervical squamous cell carcinoma. Nihon Sanka Fujinka Gakkai Zasshi 1986; 38: 2050-2056.
32. Jain NK, Kulkarni SK. Antinociceptive and antiinflammatory effects of tanacetum parthenium l. Extract in mice and rats. J Ethnopharmacol 1999; 68: 251-259.
33. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappab as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507-516.
34. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004; 208: 143-153.
35. Park JH, Liu L, Kim IH, Kim JH, You KR, Kim DG. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res 2005; 65: 2804-2814.
36. Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res 2005; 65: 6312-6320.
37. Liu JW, Cai MX, Xin Y et al. Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010; 29: 108.
38. Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999; 65: 126-129.
39. Woynarowski JM, Konopa J. Inhibition of DNA biosynthesis in hela cells by cytotoxic and antitumor sesquiterpene lactones. Mol Pharmacol 1981; 19: 97-102.
40. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM. Suppressed nf-kappab and sustained jnk activation contribute to the sensitization effect of parthenolide to tnf-alpha-induced apoptosis in human cancer cells. Carcinogenesis 2004; 25: 2191-2199.
41. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-jun n-terminal kinase. Oncogene 2004; 23: 7330-7344.
42. Patel NM, Nozaki S, Shortle NH et al. Paclitaxel sensitivity of breast cancer cells with constitutively active nf-kappab is enhanced by ikappabalpha super-repressor and parthenolide. Oncogene 2000; 19: 4159-4169.
43. Esumi H, Lu J, Kurashima Y, Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl]- 1-methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 2004; 95: 685-690.
44. Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330-341.
45. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43: S57-S69.
46. Dittmar W, Lohaus G. Hoe 296, a new antimycotic compound with a broad antimicrobial spectrum. Laboratory results. Arzneimittelforschung 1973; 23: 670-674.
47. Zhou H, Shen T, Luo Y et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer 2010; 127: 2467-2477.